GSK's Hal Bar­ron ax­es a once-prized drug from J&J, con­tin­u­ing shift away from res­pi­ra­to­ry

Hal Bar­ron’s re­vamp of the Glax­o­SmithK­line pipeline con­tin­ued yes­ter­day, as the British phar­ma an­nounced they axed an asth­ma drug they once promised over $200 mil­lion to ac­quire.

Then led by CEO An­drew Wit­ty and R&D chief Patrick Val­lance, GSK picked up the drug, known el­e­gant­ly as GSK3772847, from J&J in 2016, hop­ing to ex­pand on the beach­head in asth­ma they had es­tab­lished the year pri­or with Breo El­lip­ta. They promised up to $227 mil­lion in up­front pay­ments and mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER